Brief: Brii Biosciences Submits Demand For Arbitration Against VIR
16/04/2026 11:21
April 16 (Reuters) - Brii Biosciences Ltd 2137.HK: SUBMITS DEMAND FOR ARBITRATION AGAINST VIR ON APRIL 16, 2026 SEEKS TRANSFER OF ELEBSIRAN MANUFACTURING AND DAMAGES FROM VIR FOR ALLEGED BREACH Further company coverage: 2137.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR